Ligand Pharmaceuticals Incorporated vs Celldex Therapeutics, Inc.: Annual Revenue Growth Compared

Biotech Revenue Growth: Ligand vs. Celldex from 2014-2023

__timestampCelldex Therapeutics, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 2014358600064538000
Thursday, January 1, 2015548000071914000
Friday, January 1, 20166786000108973000
Sunday, January 1, 201712743000141102000
Monday, January 1, 20189538000251453000
Tuesday, January 1, 20193573000120282000
Wednesday, January 1, 20207418000186419000
Friday, January 1, 20214651000277133000
Saturday, January 1, 20222357000196245000
Sunday, January 1, 20236883000131314000
Loading chart...

Cracking the code

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the competitive world of biotechnology, revenue growth is a key indicator of success. Over the past decade, Ligand Pharmaceuticals Incorporated and Celldex Therapeutics, Inc. have shown contrasting trajectories. Ligand Pharmaceuticals, with its innovative drug discovery platform, has seen its revenue grow by approximately 103% from 2014 to 2023, peaking in 2021. In contrast, Celldex Therapeutics, despite its promising pipeline, experienced a more volatile revenue pattern, with a peak in 2017 and a subsequent decline, resulting in a 92% increase over the same period. This comparison highlights the challenges and opportunities within the biotech sector, where strategic partnerships and product pipelines can significantly impact financial outcomes. As the industry evolves, these companies' ability to adapt and innovate will be crucial in maintaining their growth momentum.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025